0000899243-22-028178.txt : 20220809 0000899243-22-028178.hdr.sgml : 20220809 20220809205918 ACCESSION NUMBER: 0000899243-22-028178 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20220805 FILED AS OF DATE: 20220809 DATE AS OF CHANGE: 20220809 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ceesay Abraham CENTRAL INDEX KEY: 0001722140 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39311 FILM NUMBER: 221150156 MAIL ADDRESS: STREET 1: C/O SCPHARMACEUTICALS, INC. STREET 2: 2400 DISTRICT AVENUE SUITE 310 CITY: BURLINGTON STATE: MA ZIP: 01830 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cerevel Therapeutics Holdings, Inc. CENTRAL INDEX KEY: 0001805387 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 222 JACOBS STREET STREET 2: SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02141 BUSINESS PHONE: 844-304-2048 MAIL ADDRESS: STREET 1: 222 JACOBS STREET STREET 2: SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02141 FORMER COMPANY: FORMER CONFORMED NAME: ARYA Sciences Acquisition Corp II DATE OF NAME CHANGE: 20200303 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-08-05 0 0001805387 Cerevel Therapeutics Holdings, Inc. CERE 0001722140 Ceesay Abraham C/O CEREVEL THERAPEUTICS HOLDINGS, INC. 222 JACOBS STREET, SUITE 200 CAMBRIDGE MA 02141 0 1 0 0 President Common Stock 2022-08-05 4 M 0 38424 13.17 A 38424 D Common Stock 2022-08-05 4 S 0 38424 32.50 D 0 D Common Stock 2022-08-08 4 M 0 19211 13.17 A 19211 D Common Stock 2022-08-08 4 S 0 9606 37.75 D 9605 D Common Stock 2022-08-08 4 S 0 9605 39.50 D 0 D Stock Option (Right to Buy) 13.17 2022-08-05 4 M 0 38424 0.00 D 2031-06-01 Common Stock 38424 422641 D Stock Option (Right to Buy) 13.17 2022-08-08 4 M 0 19211 0.00 D 2031-06-01 Common Stock 19211 403430 D These transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 17, 2022 adopted by the Reporting Person. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.50 - $32.51. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 25% of the shares subject to this option vested and became exercisable on June 1, 2022, with the remainder vesting in thirty-six (36) equal monthly installments thereafter. Exhibit 24 - Power of Attorney /s/ Mark Bodenrader, as Attorney-in-Fact 2022-08-09 EX-24 2 attachment1.htm EX-24 DOCUMENT

                                POWER OF ATTORNEY

        The undersigned hereby constitutes and appoints each of Mark
Bodenrader, Scott Akamine and John Mei, signing singly, and with full power of
substitution, the undersigned's true and lawful attorney-in-fact to:

        (1)    execute for and on behalf of the undersigned, in the
undersigned's capacity as officer and/or director of Cerevel Therapeutics
Holdings, Inc., a Delaware corporation (the "Company"), from time to time the
following U.S. Securities and Exchange Commission (the "SEC") forms: (i) Form
ID, including any attached documents (such as Update Passphrase
Authentication), to effect the assignment of codes to the undersigned to be
used in the transmission of information to the SEC using the EDGAR System; (ii)
Form 3, Initial Statement of Beneficial Ownership of Securities, including any
attached documents; (iii) Form 4, Statement of Changes in Beneficial Ownership
of Securities, including any attached documents; (iv) Form 5, Annual Statement
of Beneficial Ownership of Securities in accordance with Section 16(a) of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules
thereunder, including any attached documents; and (v) amendments of each
thereof, in accordance with the Exchange Act, and the rules thereunder,
including any attached documents;

        (2)    do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to complete and execute any
such Form 3, 4 or 5 or any amendment(s) thereto and timely file such form(s)
with the SEC and any securities exchange, national association or similar
authority; and

        (3)    take any other action of any type whatsoever in connection with
the foregoing which, in the opinion of such attorney-in-fact, may be of benefit
to, in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of
the undersigned pursuant to this Power of Attorney shall be in such form and
shall contain such terms and conditions as such attorney-in-fact may approve in
such attorney-in-fact's discretion.

        The undersigned hereby grants to each such attorney-in-fact, acting
singly, full power and authority to do and perform any and every act and thing
whatsoever requisite, necessary or proper to be done in the exercise of any of
the rights and powers herein granted, as fully to all intents and purposes as
the undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this power of attorney and the
rights and powers herein granted. The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Exchange Act.
The undersigned hereby agrees to indemnify the attorneys-in-fact and the
Company from and against any demand, damage, loss, cost or expense arising from
any false or misleading information provided by the undersigned to the
attorneys-in-fact.

        This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file such forms with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact. This Power of Attorney supersedes any prior power
of attorney in connection with the undersigned's capacity as an officer and/or
director of the Company. This Power of Attorney shall expire as to any
individual attorney-in-fact if such attorney-in-fact ceases to be an employee
of the Company.

        IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney
to be executed as of June 14, 2022.


                                   /s/ Abraham Ceesay
                                   -------------------------------
                                   Abraham Ceesay